P-137 - Clinical feature of 53 patients with biliary neuroendocrine tumors: Retrospective study for Korean neuroendocrine tumor of gallbladder, extrahepatic...

Date 04 July 2015
Event WorldGI 2015
Session Posters
Topics Neuroendocrine Tumours
Aetiology, Epidemiology, Screening and Prevention
Basic Scientific Principles
Presenter J.H. Cho
Citation Annals of Oncology (2015) 26 (suppl_4): 1-100. 10.1093/annonc/mdv233
Authors J.H. Cho1, H.Y. Jeong2, K.J. Lee3, W.J. Lee4, S.H. Lee5, K.H. Lee6, K.B. Park7, J.K. Lee8, C.H. Yang9
  • 1Gachon University, Incheon/KR
  • 2Chungnam National University School of Medicine, Daejeon/KR
  • 3Yonsei University Wonju College of Medicine, Wonju/KR
  • 4National Cancer Center, Goyang/KR
  • 5Seoul National University College of Medicine, Seoul/KR
  • 6Sungkyunkwan University School of Medicine, Seoul/KR
  • 7National Health Insurance Corporation Ilsan Hospita, Goyang/KR
  • 8Dongguk University Ilsan Hospital, Goyang/KR
  • 9Dongguk University College of Medicine, Gyeongju/KR



Neuroendocrine tumor (NET) in biliary organs are very rare and their clinical behavior is unknown. The aim of study is to assess the clinicopathological features, therapeutic approach and prognosis of these patients


“The Korean Society of Gastrointestinal Cancer” conducted “the Korean Gastroenteropancreatic Neuroendocrine Tumor Study” and made a multicenter retrospective study of 53 cases of gallbladder (GB), extrahepatic bile duct (EHD) and ampulla of Vater (AoV) NET and mixed adenoneuroendocrine carcinoma (MANEC) between 2005 and 2014.


A total of 53 patients were enrolled (mean age 62.0 ±13.6, 53% male). The most common symptoms were abdominal discomfort (45%) and jaundice (28%). Primary sites of NET were as follows: GB, EHD, and AoV were 16 (30.2%), 5 (9.4%) and 32 (60.4%). Based on the WHO 2010 classification, 14 (26.4%) patients had NET G1, 4 (7.5%) NET G2, 25 (47.2%) NET G3 and 10 (18.9%) MANEC. Among them, 12 (23%) patients experienced hepatic and lymph node metastasis on the initial diagnosis (7 GB, 5 AoV; 1 NET G2, 9 NET G3, 2 MANEC). Progression free survivals (PFS) of AoV NET and NET G1/2 were significantly longer than GB/EHD NET and NET G3/MANAC. (45.6 vs. 7.6 months, p < 0.01; 82.6 vs. 7.1 months p < 0.01) In addition, Cox proportional hazard model with NET sites, grades, age and metastasis showed that WHO 2010 grade is only significant indicator for PFS of biliary NET. (NET G3/MANEC vs. NET G1/2, HR 39.6, CI 5.1-310.2, p < 0.01)


Patients with gallbladder, extrahepatic bile duct and ampulla of Vater showed different clinical outcomes according to histopathology subtypes by WHO 2010 classification and the primary tumor sites.

Table: P-137. Progression free survival according to biliary NET sites and WHO 2010 grades